Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2000
11/23/2000WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000037067A9 Sensitizing agents for the treatment of skin lesions
11/23/2000WO2000036918A9 Methods and compositions for treatment of cell proliferative disorders
11/23/2000WO2000035920A3 4,5-azolo-oxindoles
11/23/2000WO2000034295A3 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000031242A3 Engineered cytotoxic ribonuclease
11/23/2000WO2000031100A3 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
11/23/2000WO2000031081A3 Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof
11/23/2000WO2000027194A9 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
11/23/2000WO2000026348A3 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
11/23/2000WO2000023053A3 Artificial antigen-specific cells and related methods
11/23/2000WO2000020450A3 Calcium channel alpha-2/delta gene
11/23/2000WO2000015666A3 Compositions and methods for the treatment of tumors
11/23/2000WO2000012127A3 Dna cancer vaccine and methods for its use
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO1999061398A3 24-hydroxyvitamin d, analogs and uses thereof
11/23/2000DE19922462A1 New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease
11/23/2000CA2767116A1 Adjuvant combination formulations
11/23/2000CA2374559A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
11/23/2000CA2374085A1 Tumour treatment with anti-erbb2 antibodies
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2374013A1 Protein a based binding domains with desirable activities
11/23/2000CA2373938A1 Compositions and methods for treating cell proliferation disorders
11/23/2000CA2373931A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000CA2373824A1 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
11/23/2000CA2373815A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373610A1 Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
11/23/2000CA2373500A1 Hydroxamic acid derivatives as matrix metalloprotease inhibitors
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372919A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000CA2372794A1 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
11/23/2000CA2372435A1 Recombinant human mannan-binding lectin
11/23/2000CA2372429A1 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000CA2372128A1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
11/23/2000CA2372098A1 Lawsonia derived gene and related flge polypeptides, peptides and proteins and their uses
11/23/2000CA2372051A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000CA2372044A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000CA2372032A1 Compounds and therapeutic methods
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2369397A1 Combined approach to treatment of cancer with hcg vaccines
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053751A1 Compositions and methods for treating cell proliferation disorders
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053746A1 Use of biodegradable microspheres for the delivery of a anticancer agent for the treatment of glioblastoma
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053332A1 Protein
11/22/2000EP1053325A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
11/22/2000EP1053323A2 Human receptor proteins
11/22/2000EP1053320A2 Human transport-associated molecules
11/22/2000EP1053316A1 Nucleic acids provided for modulating cellular activation
11/22/2000EP1053313A1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053301A1 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
11/22/2000EP1053256A1 Antibodies to death receptor 4 (dr4) and uses thereof
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053224A1 Biphenylsulfonyl cyanamides, method for the production thereof and their utilization as a medicament
11/22/2000EP1053023A2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy
11/22/2000EP1053022A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/22/2000EP1052974A2 Compositions containing organic compounds
11/22/2000EP0725637B1 Parenteral busulfan for treatment of malignant disease
11/22/2000EP0705255B1 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes
11/22/2000EP0703988B1 Mesothelial cell gene therapy
11/22/2000EP0586535B1 Methods and compositions based on inhibition of cell invasion and fibrosis by dextran sulfate
11/22/2000CN1274344A Novel vitamin D analogues
11/22/2000CN1274287A Compsn. and method of treating cancer with tannic acid and tannin complexes
11/22/2000CN1274285A Alpha-ketoamide multicatalytic protease inhibitors
11/22/2000CN1274284A Methods of modulating serine/threnoine protein kinase function with 5-azaquinoxaline-based compounds
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/22/2000CN1273974A Camptothecin derviative, its prepn. method and medicinal compsns. containing same
11/22/2000CN1273967A Novel substituted dimeric compounds, its preparing process and medicinal compsns. containing same
11/22/2000CN1273860A Medicine for treating blood vessel embolism and its preparing process
11/22/2000CN1273836A Fumaitong liquid and its preparing process
11/22/2000CN1273831A Medicie for treating gastritis and pathologic affection before gastromucosa cancer
11/22/2000CN1058636C Medicine for preventing liver cancer
11/22/2000CN1058620C External-use Chinese patent drug for treating cancer, and its prodn. tech.
11/22/2000CN1058610C Immunologic facilitation agent for inhibiting growth of tumor
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150508 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
11/21/2000US6150502 Polypeptides expressed in skin cells
11/21/2000US6150415 Epoxide hydrolase complexes and methods therewith
11/21/2000US6150413 Treatment of dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as mammalian skin and hair conditions; 4-(4-(biphenyl-2-yl)but-3-en-1-ynyl)benzoic acid, for example
11/21/2000US6150407 In a tissue or organ by contacting with a compound of given formula such as methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate; reducing the level of tumor necrosis factor alpha
11/21/2000US6150377 Farnesyl protein transferase inhibitors; anticarcinogenic,-tumor and -proliferative agents; also psoriasis, benign prostatic hypertrophy or restinosis; infections facilitated by farnesyl protein transferase, e.g., malaria or hepatitus delta
11/21/2000US6150375 Inhibitors of both of the human 5ar isozymes; benign prostate hyperplasia, male pattern baldness, acne vulgaris, seborrhea, androgenic alopecia, hirsutism and prostate cancer; blocks the conversion of testosterone to 5-alpha-dihydrotestosterone
11/21/2000US6150373 Bicyclic nitrogen heterocycles
11/21/2000US6150370 1,3-dinitrocyclic compound treats numerous diseases caused by undesired metalloprotease activity, such as tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, and periodontitis
1 ... 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 ... 2211